(EVK) Evonik Industries - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: XETRA (Germany) | Market Cap: 8.299m EUR | Total Return: -9.2% in 12m
Avg Turnover: 23.1M
EPS Trend: 43.5%
Qual. Beats: 0
Rev. Trend: -90.6%
Qual. Beats: -1
Warnings
Below Avwap Earnings
Tailwinds
Confidence
Evonik Industries AG is a German specialty chemicals manufacturer headquartered in Essen, operating across five continents. The company organizes its production into three primary segments: Advanced Technologies, Custom Solutions, and Infrastructure. Its portfolio includes high-performance polymers, additives, crosslinkers, and essential amino acids for animal nutrition.
The business model focuses on high-margin specialty chemicals rather than high-volume commodities, allowing for greater integration into specialized supply chains like medical technology and automotive engineering. In the specialty chemicals sector, competitive advantage is often driven by proprietary formulations and the ability to meet stringent regulatory standards for pharmaceutical and food-grade applications.
For a deeper dive into these business segments and their historical performance, ValueRay provides comprehensive data tools.
Evonik serves diverse end-markets, providing hydrogen peroxide for electronics manufacturing, silicas for tire production, and plasticizers for the construction industry. Founded in 1847, the firm maintains a significant infrastructure division that supports the production of essential chemical precursors like butadiene and MTBE for the global rubber and fuel markets.
- Cyclical demand for animal nutrition methionine impacts specialty chemical segment margins
- Fluctuating energy and raw material costs in Germany pressure operational profitability
- Global automotive and tire production volumes drive demand for silica and silanes
- Strategic shift toward high-margin specialty chemicals reduces exposure to volatile commodities
- European environmental regulations and carbon pricing increase long-term manufacturing overhead costs
| Net Income: 157.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.10 > 1.0 |
| NWC/Revenue: 13.35% < 20% (prev 14.49%; Δ -1.13% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.39b > Net Income 157.0m |
| Net Debt (4.43b) to EBITDA (1.76b): 2.51 < 3 |
| Current Ratio: 1.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (466.0m) vs 12m ago 0.0% < -2% |
| Gross Margin: 22.59% > 18% (prev 0.25%; Δ 2.23k% > 0.5%) |
| Asset Turnover: 70.91% > 50% (prev 74.79%; Δ -3.88% > 0%) |
| Interest Coverage Ratio: 2.59 > 6 (EBITDA TTM 1.76b / Interest Expense TTM 217.0m) |
| A: 0.10 (Total Current Assets 5.43b - Total Current Liabilities 3.60b) / Total Assets 18.46b |
| B: 0.39 (Retained Earnings 7.21b / Total Assets 18.46b) |
| C: 0.03 (EBIT TTM 561.0m / Avg Total Assets 19.35b) |
| D: 0.70 (Book Value of Equity 7.06b / Total Liabilities 10.16b) |
| Altman-Z'' = 2.85 = A |
| DSRI: 1.08 (Receivables 1.82b/1.87b, Revenue 13.72b/15.14b) |
| GMI: 1.09 (GM 22.59% / 24.74%) |
| AQI: 1.01 (AQ_t 0.33 / AQ_t-1 0.33) |
| SGI: 0.91 (Revenue 13.72b / 15.14b) |
| TATA: -0.07 (NI 157.0m - CFO 1.39b) / TA 18.46b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of May 23, 2026, the stock is trading at EUR 17.34 with a total of 1,766,840 shares traded.
Over the past week, the price has changed by -2.98%,
over one month by -1.14%,
over three months by +13.46% and
over the past year by -9.15%.
Evonik Industries has no consensus analysts rating.
P/E Trailing = 52.3824
P/E Forward = 19.9203
P/S = 0.605
P/B = 0.9935
P/EG = 6.2284
Revenue TTM = 13.72b EUR
EBIT TTM = 561.0m EUR
EBITDA TTM = 1.76b EUR
Long Term Debt = 2.59b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 684.0m EUR (from shortTermDebt, last quarter)
Debt = 5.02b EUR (from shortLongTermDebtTotal, last quarter) + Leases 865.0m
Net Debt = 4.43b EUR (calculated: Debt 5.02b - CCE 589.0m)
Enterprise Value = 12.73b EUR (8.30b + Debt 5.02b - CCE 589.0m)
Interest Coverage Ratio = 2.59 (Ebit TTM 561.0m / Interest Expense TTM 217.0m)
EV/FCF = 20.84x (Enterprise Value 12.73b / FCF TTM 611.0m)
FCF Yield = 4.80% (FCF TTM 611.0m / Enterprise Value 12.73b)
FCF Margin = 4.45% (FCF TTM 611.0m / Revenue TTM 13.72b)
Net Margin = 1.14% (Net Income TTM 157.0m / Revenue TTM 13.72b)
Gross Margin = 22.59% ((Revenue TTM 13.72b - Cost of Revenue TTM 10.62b) / Revenue TTM)
Gross Margin QoQ = 25.21% (prev 20.25%)
Tobins Q-Ratio = 0.69 (Enterprise Value 12.73b / Total Assets 18.46b)
Interest Expense / Debt = 1.02% (Interest Expense 51.0m / Debt 5.02b)
Taxrate = 29.51% (54.0m / 183.0m)
NOPAT = 395.5m (EBIT 561.0m * (1 - 29.51%))
Current Ratio = 1.51 (Total Current Assets 5.43b / Total Current Liabilities 3.60b)
Debt / Equity = 0.61 (Debt 5.02b / totalStockholderEquity, last quarter 8.23b)
Debt / EBITDA = 2.51 (Net Debt 4.43b / EBITDA 1.76b)
Debt / FCF = 7.25 (Net Debt 4.43b / FCF TTM 611.0m)
Total Stockholder Equity = 8.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.81% (Net Income 157.0m / Total Assets 18.46b)
RoE = 1.89% (Net Income TTM 157.0m / Total Stockholder Equity 8.30b)
RoCE = 5.15% (EBIT 561.0m / Capital Employed (Equity 8.30b + L.T.Debt 2.59b))
RoIC = 2.64% (NOPAT 395.5m / Invested Capital 14.95b)
WACC = 4.11% (E(8.30b)/V(13.32b) * Re(6.17%) + D(5.02b)/V(13.32b) * Rd(1.02%) * (1-Tc(0.30)))
Discount Rate = 6.17% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -3.62 | Cagr: 0.0%
[DCF] Terminal Value 86.57% ; FCFF base≈723.8m ; Y1≈740.8m ; Y5≈823.2m
[DCF] Fair Price = 42.84 (EV 24.40b - Net Debt 4.43b = Equity 19.97b / Shares 466.0m; r=6.0% [WACC]; 5y FCF grow 2.21% → 3.0% )
EPS Correlation: 43.47 | EPS CAGR: 12.31% | SUE: 0.71 | # QB: 0
Revenue Correlation: -90.64 | Revenue CAGR: -5.67% | SUE: -2.07 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.48 | Chg30d=N/A | Revisions=+20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.44 | Chg30d=N/A | Revisions=+20% | Analysts=2
EPS current Year (2026-12-31): EPS=1.61 | Chg30d=+32.80% | Revisions=+56% | GrowthEPS=+18.2% | GrowthRev=+4.3%
EPS next Year (2027-12-31): EPS=1.41 | Chg30d=+2.07% | Revisions=+45% | GrowthEPS=-12.5% | GrowthRev=-1.2%
[Analyst] Revisions Ratio: +56%